Diabetes medications with cardiovascular protection in the wake of EXSCEL: is there a class effect for long-acting GLP-1 receptor agonists?

[1]  G. Dagenais,et al.  Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide , 2018, Diabetes, obesity & metabolism.

[2]  Neha J. Pagidipati,et al.  Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.

[3]  R. DeFronzo,et al.  What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives? , 2017 .

[4]  J. Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[5]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[6]  R. DeFronzo,et al.  Diabetes medications with cardiovascular protection – what now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives? , 2016 .

[7]  S. Solomon,et al.  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.

[8]  R. DeFronzo,et al.  Diabetes medications with cardiovascular protection in the wake of EMPA-REG OUTCOME: The optimal combination may be metformin, pioglitazone and empagliflozin , 2015 .

[9]  R. Ryder The potential risks of pancreatitis and pancreatic cancer with GLP‐1‐based therapies are far outweighed by the proven and potential (cardiovascular) benefits , 2013, Diabetic medicine : a journal of the British Diabetic Association.